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Background
Approximately 4% of black Americans carry a valine-to-isoleucine substitution 
(V122I) in the transthyretin protein, which has been associated with late-onset re-
strictive amyloid cardiomyopathy and increased risks of death and heart failure.
Methods
We determined genotype status for the transthyretin gene (TTR) in 3856 black par-
ticipants in the Atherosclerosis Risk in Communities study and assessed clinical 
profiles, mortality, and the risk of incident heart failure in V122I TTR variant carri-
ers (124 participants [3%]) versus noncarriers (3732 participants). Cardiac structure 
and function and features suggestive of cardiac amyloidosis were assessed in par-
ticipants who underwent echocardiography during visit 5 (2011 to 2013), when they 
were older than 65 years of age.
Results
After 21.5 years of follow-up, we did not detect a significant difference in mortality 
between carriers (41 deaths, 33%) and noncarriers (1382 deaths, 37%; age- and sex-
stratified hazard ratio among carriers, 0.99; 95% confidence interval [CI], 0.73 to 
1.36; P = 0.97). The TTR variant was associated with an increased risk of incident 
heart failure (age- and sex-stratified hazard ratio, 1.47; 95% CI, 1.03 to 2.10; P = 0.04). 
On echocardiography at visit 5, carriers (46 participants) had worse systolic and 
diastolic function, as well as a higher level of N-terminal pro–brain natriuretic pep-
tide, than noncarriers (1194 participants), although carriers had a low prevalence (7%) 
of overt manifestations of amyloid cardiomyopathy.
Conclusions
We did not detect a significant difference in mortality between V122I TTR allele 
carriers and noncarriers, a finding that contrasts with prior observations; however, 
the risk of heart failure was increased among carriers. The prevalence of overt car-
diac abnormalities among V122I TTR carriers was low. (Funded by the National Heart, 
Lung, and Blood Institute and others.)
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A myloid heart disease leads to an increase in ventricular wall thickness and stiffness of the heart.1 Abnormalities of 
transthyretin, a transport protein synthesized 
mainly by the liver, may lead to hereditary trans-
thyretin-related amyloidosis.2 This disorder can 
be caused by any one of more than 100 point mu-
tations in the transthyretin gene (TTR); the V122I 
variant, in which isoleucine is substituted for va-
line at position 122, is the most frequent muta-
tion and occurs in 3 to 4% of black Americans.3-5 
V122I reduces the stability of transthyretin tetra-
mers, causing cardiac deposition of misfolded 
transthyretin monomers and resulting in an au-
tosomal dominant cardiomyopathy that typically 
occurs during or after the sixth decade of life, 
with a penetrance believed to be as high as 80% 
among men.6-9 The variant has been associated 
with increased risks of heart failure and death.
Although progressive heart failure can devel-
op in persons with echocardiographically typical 
amyloid cardiomyopathy, the relatively few pub-
lished reports may have involved a highly selected 
group of persons with this variant and thus may 
not reflect its true clinical significance.9 We evalu-
ated an unbiased sample of blacks who carry the 
V122I TTR variant to assess the effect of the 
variant on long-term morbidity and mortality and 
to determine the prevalence of abnormalities of 
cardiac structure and function in allele carriers 
beyond the sixth decade of life.
Me thods
The Atherosclerosis Risk in Communities 
Study
The Atherosclerosis Risk in Communities (ARIC) 
study is an ongoing, prospective, observational 
study that is designed to analyze the natural his-
tory of atherosclerotic diseases and risk factors 
for cardiovascular disease. The study rationale, 
design, and procedures have been published pre-
viously.10 Of the 15,792 persons 44 to 66 years of 
age who were recruited between 1987 and 1989 
from four communities in the United States, 4266 
(27%) reported themselves to be black.
Follow-up visits occurred approximately every 
3 years through 1998, with annual telephone inter-
views conducted between visits. A limited number 
of structural and functional echocardiographic 
variables were assessed in black participants dur-
ing visit 3, which occurred between 1993 and 1995. 
Participants returned for visit 5 between June 2011 
and August 2013, during which a broad range of 
clinical, laboratory, and echocardiographic data 
were obtained. The institutional review board at 
each site approved the study, and all participants 
provided written informed consent.
Study Population and Study Design
Figure S1 in the Supplementary Appendix (avail-
able with the full text of this article at NEJM.org) 
shows the enrollment and follow-up of the study 
population included in the present analysis. The 
nonsynonymous V122I TTR variant (rs76992529) 
was determined by genotyping with the Illumina 
HumanExome BeadChip, version 1.0. The meth-
ods of genotyping, allele calling, and quality 
control have been published previously.11 V122I 
TTR genotype information was unavailable for 
410 of the 4266 black participants in the ARIC 
study, owing to a lack of available DNA, poor 
genotyping performance with the array, or a lack 
of consent, leaving 3856 participants in this 
analysis, of whom 124 (3%) were carriers and 
3732 were noncarriers (Fig. S1 in the Supplemen-
tary Appendix). Only 2 (<0.1%) of the 10,893 non-
black participants who provided consent for geno-
typing had the V122I variant.
Event Ascertainment
Outcomes were ascertained during follow-up vis-
its for the ARIC study as well as through annual 
calls to participants, ongoing surveillance of 
health department certificate files, and review of 
local hospital-discharge lists (with outcomes de-
termined on the basis of International Classification 
of Diseases codes) and death certificates. This 
method of ascertainment of outcomes has been 
reported previously and validated.12,13
Echocardiography
Echocardiograms were obtained at visit 5 (be-
tween 2011 and 2013) according to a study-spe-
cific protocol and were analyzed in a core labora-
tory; the protocol and reproducibility have been 
described previously.14,15 Echocardiographic data 
were available for 1240 participants with geno-
type status. Left ventricular function was also as-
sessed by means of speckle-tracking echocar-
diography (TomTec Imaging Systems).16,17 All 
echocardiographic assessments were performed 
by persons who were unaware of the partici-
pants’ V122I genotype status. Echocardiograms 
showing a left ventricular wall thickness of more 
than 12 mm1,18 were reviewed by an investigator 
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who was unaware of carrier status to identify 
features suggestive of cardiac amyloidosis, in-
cluding granular sparkling of the ventricular myo-
cardium, increased thickness of the atrioventricu-
lar valve or interatrial septum, and pericardial 
effusion.
Statistical Analysis
Clinical characteristics of ARIC study partici-
pants were assessed as described previously.19,20 
Using Cox regression, we estimated age- and sex-
stratified hazard ratios to determine the associa-
tion between the TTR variant and the risk of 
Table 1. Characteristics of All Participants with Known Genotype Status at Visit 1 and of Those Who Underwent Echocardiographic 
Evaluation at Visit 5.*
Characteristic
All Participants with Known V122I TTR  
Genotype Status
Participants with Known V122I TTR  









(N = 46) P Value
Age — yr
Median 53 52 0.39 50 50 0.32
IQR 48–58 48–57 47–54 47–53
Male sex — no. (%) 1408 (38) 45 (36) 0.75 406 (34) 11 (24) 0.16
Body-mass index†
No. of patients with data 3721 124 1192 46
Mean 30±6 29±6 0.35 29±5 28±5 0.10
Systolic blood pressure
No. of patients with data 3729 124 1193 46
Mean — mm Hg 129±21 131±20 0.14 123±17 126±16 0.24
Diastolic blood pressure
No. of patients with data 3729 124 1193 46
Mean — mm Hg 80±12 82±13 0.09 79±11 81±12 0.22
Heart rate
No. of patients with data 3693 123 1187 45
Mean — beats/min 67±11 68±11 0.24 66±10 71±9 0.001
Systolic blood pressure ≥140 mm Hg  
— no./total no. (%)
937/3729 (25) 38/124 (31) 0.16 156/1193 (13) 10/46 (22) 0.09
Diastolic blood pressure ≥90 mm Hg  
— no./total no. (%)
648/3729 (17) 30/124 (24) 0.05 163/1193 (14)  9/46 (20) 0.26
Hypertension — no./total no. (%) 2068/3714 (56) 72/123 (59) 0.53 515/1188 (43) 20/46 (43) 0.99
Antihypertensive medication — no./total no. (%) 1507/3712 (41) 50/123 (41) 0.99 384/1188 (32) 12/46 (26) 0.37
Diabetes — no./total no. (%) 715/3637 (20) 25/121 (21) 0.79 100/1167 (9) 3/46 (7) 0.79
Lipid-lowering medication — no./total no. (%) 53/3679 (1) 2/123 (2) 0.87 10/1174 (1) 0/46 1.00
Current smoker — no./total no. (%) 1103/3726 (30) 34/123 (28) 0.64 263/1192 (22)  8/46 (17) 0.45
Creatinine
No. of patients with data 3628 123 1165 46
Median (IQR) — mg/dl 0.9 (0.8–1.0) 0.9 (0.8–1.0) 0.65 0.9 (0.8–1.0) 0.9 (0.8–1.0) 0.66
Estimated GFR
No. of patients with data 3628 123 1065 46
Median (IQR) — ml/min/1.73 m2 of body-
surface area
102 (87–119) 102 (89–119) 0.69 103 (89–120) 103 (91–108) 0.97
Prevalent heart failure — no./total no. (%) 245/3676 (7) 10/122 (8) 0.51 48/1185 (4) 4/46 (9) 0.12
* Plus–minus values are means ±SD. Between-group differences were analyzed with the use of Fisher’s exact test or Pearson’s chi-square test 
for categorical variables and the Mann–Whitney U test or t-test for continuous variables. To convert values for creatinine values to micro-
moles per liter, multiply by 88.4. GFR denotes glomerular filtration rate, and IQR interquartile range.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
The New England Journal of Medicine 
Downloaded from nejm.org on June 21, 2018. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 372;1 nejm.org january 1, 201524
death or incident heart failure. In the subgroup 
of participants who were alive and free from 
heart failure at 53 years of age, we estimated the 
mean time to death and time to incident heart 
failure, to a maximum of 30 years. In the heart-
failure analyses, we excluded participants who 
had prevalent heart failure or for whom informa-
tion on heart-failure status at baseline was miss-
ing. We used multiple imputation to account for 
missing echocardiographic data at visit 5 among 
living participants (see the Supplementary Ap-
pendix), and among participants who died before 
visit 5, we compared the echocardiographic data 
of carriers and noncarriers from visit 3. We as-
sessed whether an age older than 80 years or an 
age of 80 years or younger modified the relation-
ship between carrier status and mortality. Final-
ly, we performed a meta-analysis of the effect of 
the variant allele on the incidence of heart failure 
by combining our results with those of the Car-
diovascular Health Study (see the Supplementary 
Appendix).8 Two-sided P values of less than 0.05 
were considered to indicate statistical signifi-
cance. Analyses were performed with the use of 
Stata software, version 12.0 (StataCorp), or R 
software, version 3.0.1 (www.r-project.org). A de-
tailed description of the statistical methods is 
available in the Supplementary Appendix.
R esult s
Study Population
At visit 1, there were no significant differences 
between carriers and noncarriers with respect to 
demographic, clinical, and laboratory character-
istics, including the prevalence of cardiovascular 
risk factors and heart failure (Table 1). Among 
participants who underwent echocardiography 
during visit 5, the characteristics of carriers were 
similar to those of noncarriers, except that the 
heart rate was significantly higher among carri-
ers (Table 1).
Outcomes
The median duration of follow-up was 21.5 years 
(interquartile range, 17.1 to 22.5), yielding 2334 
person-years among carriers and 70,519 person-
years among noncarriers. There were 41 deaths 
among carriers (33%; 1.76 deaths per 100 per-
son-years) and 1382 deaths among noncarriers 
(37%; 1.96 deaths per 100 person-years) (age- 
and sex-stratified hazard ratio among carriers, 
0.99; 95% confidence interval [CI], 0.73 to 1.36; 
P = 0.97) (Fig. 1A). Incident heart failure was ob-
served in 32 of 112 carriers (29%; 1.59 cases per 
100 person-years) and 698 of 3431 noncarriers 
(20%; 1.12 cases per 100 person-years) (stratified 
hazard ratio, 1.47; 95% CI, 1.03 to 2.10; P = 0.04) 
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Figure 1. Kaplan–Meier Curves for Overall Survival and Freedom from 
Heart Failure, According to Genotype Status.
The analysis, which included black participants in the Atherosclerosis Risk 
in Communities study, compared carriers of the amyloidogenic V122I trans-
thyretin variant with noncarriers of the variant. Survival estimates as a 
function of time from visit 1 were obtained.
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cant interaction between carrier status and sex 
for either end point (P = 0.29 for survival and 
P = 0.87 for freedom from heart failure), the haz-
ard ratios for death and heart failure among car-
riers as compared with noncarriers were 1.20 
(95% CI, 0.77 to 1.86) and 1.54 (95% CI, 0.88 to 
2.71), respectively, among men and 0.84 (95% CI, 
0.54 to 1.32) and 1.42 (95% CI, 0.89 to 2.26), re-
spectively, among women (Fig. S2 in the Supple-
mentary Appendix).
We did not observe a significant difference in 
the time to death after 53 years of age according 
to genotype status (Fig. 2A). In contrast, time 
free from heart failure during this interval was 
2.0 years (95% CI, 0.1 to 3.8) shorter among liv-
ing carriers than among living noncarriers (23.9 
years [95% CI, 22.0 to 25.7] vs. 25.9 years [95% 
CI, 25.6 to 26.2], P = 0.04) (Fig. 2B). We detected 
a nonsignificant trend toward an increase in the 
risk of death associated with mutation among 
participants older than 80 years of age (hazard 
ratio, 2.01; 95% CI, 0.74 to 5.47) versus those 80 
years of age or younger (hazard ratio, 0.93; 95% 
CI, 0.67 to 1.29; P = 0.15 for interaction). A meta-
analysis in which the results of our study were 
combined with those of the Cardiovascular 
Health Study8 showed a combined hazard ratio 
for incident heart failure of 1.45 (95% CI, 1.04 to 
2.02; P = 0.03) among V122I TTR variant carriers 
(Fig. 3).
Clinical and Echocardiographic Profiles  
at Visit 5
Among participants who attended visit 5, the 
clinical characteristics of carriers were similar to 
those of noncarriers, with the exception of the 
level of N-terminal pro–brain natriuretic peptide 
(NT-proBNP), which was significantly higher 
among carriers (Table S1 in the Supplementary 
Appendix). As compared with noncarriers, carri-
ers had worse indexes of systolic function (e.g., a 
lower lateral mitral systolic velocity and a less 
negative value for global longitudinal strain) and 
diastolic function (e.g., a higher ratio of early mi-
tral inflow velocity to lateral mitral early relax-
ation velocity and a higher ratio of early mitral 
inflow velocity to late mitral inflow velocity) in 
both adjusted and unadjusted analyses (Table 2). 
Only 5 carriers (11%) and 111 noncarriers (9%) 
had a mean left ventricular wall thickness of 
more than 1.2 cm.18 Three carriers (7%) and 11 
noncarriers (1%) showed severe symmetric left 
ventricular wall thickening and features sugges-
tive of an infiltrative phenotype (P = 0.01). Al-
though genotype status was unknown for ap-
proximately 10% of black participants in the 
ARIC study, there were minimal differences be-
tween those with a known genotype status and 

































































































Figure 2. Kaplan–Meier Curves, with Age as the Underlying Time Variable, 
for Overall Survival and Freedom from Heart Failure, According to Geno-
type Status.
Participants with prevalent heart failure at the time of the first evaluation or 
for whom information on heart-failure status at baseline was missing were 
excluded from the analysis.
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To account for missing echocardiographic 
data from living participants at visit 5, we per-
formed a multiple imputation analysis, which 
included 2154 noncarriers and 76 carriers. The 
results of these analyses were similar to those of 
the primary analyses, with significant differ-
ences observed between carriers and noncarriers 
in measures of systolic and diastolic function 
(Table S3 in the Supplementary Appendix). An 
analysis of limited echocardiographic data avail-
able for a subgroup of participants at visit 3 
(1993 to 1995) showed that left ventricular wall 
thickness was increased to a similar extent in 
carriers and noncarriers who died before visit 5 
(wall thickness, 1.25±0.21 cm and 1.27±0.24 cm, 
respectively; P = 0.70).
Discussion
We did not detect higher mortality among black 
carriers of the V122I TTR variant than among 
black noncarriers over long-term follow-up — a 
finding that was contrary to findings from a few 
small studies of patients who were referred pri-
marily because of heart-failure symptoms or car-
diac abnormalities; however, we did find a higher 
incidence of heart failure among carriers. The 
clinical penetrance of the V122I allele among 
men was shown in prior studies to be approxi-
mately 80%7-9; in contrast, the vast majority of 
carriers in our study, at an average age of 74 years 
and approximately two decades after initial eval-
uation, had no overt manifestations of amyloid 
cardiomyopathy. However, they did have subtle 
abnormalities of systolic and diastolic function, 
and their level of NT-proBNP was higher than 
that of noncarriers.
The published literature on the V122I TTR 
variant consistently describes a phenotype of 
restrictive cardiomyopathy with marked left ven-
tricular wall thickening in the late stage of the 
disease after a latent period of asymptomatic 
increase in left ventricular mass, which suggests 
that a considerable amyloid load is required be-
fore the development of heart failure. Despite 
the high prevalence of the V122I variant among 
blacks, the clinical penetrance of this variant 
has not been clearly defined, although it is be-
lieved that the variant has no discernible effect 
on cardiac function and mortality before a per-
son is 60 years of age.8
On the basis of prior reports,7-9 we antici-
pated that among elderly persons there would be 
significant differences in left ventricular wall 
thickness and other echocardiographic manifes-
tations of cardiac amyloidosis between carriers 
and noncarriers. However, the prevalence of 
overt cardiac abnormalities among carriers was 
considerably lower than expected, suggesting 
that prior reports may have been influenced by 
referral bias. Nevertheless, the subtle structural 
and functional abnormalities and increased NT-
proBNP level in carriers could presage more se-
vere abnormalities with increasing age. These 
findings suggest that there may be mechanisms 
other than extensive amyloid infiltration of the 
myocardium by which V122I contributes to 
heart failure, including a synergistic effect with 
other risk factors such as hypertension. Thus, 
carriers with little or no infiltration and mini-
mal coexisting disease might remain asymptom-
atic, whereas those with other risk factors might 
manifest disease. This construct would be con-
sistent with autopsy data from elderly V122I 
carriers, in whom some degree of amyloid depo-
sition is almost universally present.3
Male sex has been described as predominant 
in the V122I TTR variant, with an estimated 
prevalence of 78 to 82%.21,22 Despite a high pro-
portion of women in the ARIC study, we did not 
observe any significant differences in either 
outcome according to sex, though the small 
number of men at visit 5 did not allow us to rule 
0.32 1.00 3.15
Hazard Ratio among V122I TTR














Figure 3. Hazard Ratios for Congestive Heart Failure among V122I TTR 
Variant Carriers as Compared with Noncarriers in Two Population-Based 
Longitudinal Studies.
A fixed-effect meta-analysis was performed with the use of the inverse-
variance method. The size of each box is proportional to the number of 
events in each study; horizontal lines indicate 95% confidence intervals. 
The dashed red line indicates the overall hazard ratio, with the blue dia-
mond showing the 95% confidence interval for the overall hazard ratio. 
The I2 statistic describes the percentage of variation across studies that  
is due to heterogeneity rather than chance.
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Table 2. Echocardiographic Findings in Noncarriers versus Carriers of the V122I TTR Allele at Visit 5.*






No. of Patients  
with Data Value
No. of Patients 
with Data
Interventricular septum thickness — cm 1.1±0.2 1187 1.1±0.2 46 0.63 0.49
Posterior wall thickness — cm 0.9±0.2 1188 1.0±0.2 46 0.08 0.04
Relative wall thickness‡ 0.44±0.09 1184 0.47±0.16 46 0.05 0.04
LV mass — g 149±46 1184 154±47 46 0.48 0.31
LV wall thickness — no. of patients (%)
>1 cm  521 (44) 1189 24 (52) 46 0.26 0.17
>1.2 cm 111 (9) 1189  5 (11) 46 0.73 0.61
Symmetric LV hypertrophy — no. of patients (%)  986 (83) 1185 40 (87) 46 0.50 0.50
LV mass index
Calculated as g/m2 of body-surface area 78±22 1184 83±22 46 0.16 0.11
Calculated as g/m2.7 of height 38±12 1183 40±12 46 0.38 0.45
LV end-diastolic diameter — cm 4.3±0.5 1184 4.3±0.6 46 0.98 0.85
LV end-systolic diameter — cm 2.6±0.5 1184 2.7±0.7 46 0.13 0.06
LV end-diastolic volume — ml 84±25 1125 88±27 43 0.33 0.12
LV end-diastolic volume index — ml/m2.7 of height 21±6 1124 22±6 43 0.31 0.27
LV end-systolic volume — ml
Median 28 1125 28 43 0.43 0.14
IQR 22–35 22–37
LV end-systolic volume index — ml/m2.7 of height
Median 7.1 1125 7.1 43 0.27 0.21
IQR 5.8–8.8 6.0–9.4
LV ejection fraction — % 65±7 1125 63±9 43 0.27 0.16
Stroke volume — ml 65±15 1185 62±15 45 0.20 0.18
Stroke volume index
Calculated as ml/m2 of body-surface area 34±8 1184 34±9 45 0.57 0.46
Calculated as ml/m2.7 of height 17±4 1185 16±5 45 0.32 0.12
Cardiac output — liters/min 4.1±1.1 1175 4.1±1.0 45 0.79 0.73
Cardiac index — liters/min/m2 of body-surface area 2.2±0.5 1173 2.2±0.5 45 0.64 0.76
Left atrial volume index
Calculated as ml/m2 of body-surface area 26±9 1178 28±10 45 0.12 0.11
Calculated as ml/m2.7 of height 13±5 1177 14±5 45 0.31 0.38
E-wave deceleration time — msec 197±44 1189 187±45 45 0.12 0.14
Ratio of early mitral inflow velocity to late mitral inflow velocity 0.8±0.3 1161 0.9±0.5 43 0.02 0.02
Lateral mitral early relaxation velocity — cm/sec 7.1±2.1 1188 6.5±1.9 45 0.11 0.10
Ratio of early mitral inflow velocity to lateral mitral early 
relaxation velocity
10.1±3.9 1186 11.6±4.3 45 0.01 0.01
Lateral mitral systolic velocity — cm/sec 7.2±1.6 1159 6.7±1.5 44 0.05 0.04
Tricuspid regurgitation velocity — cm/sec 240±32 712 242±30 29 0.74 0.73
LV global longitudinal strain — % −17.4±2.8 1125 −16.6±2.6 41 0.05 0.02
Abnormal LV global longitudinal strain — no. of patients (%) 902 (80) 1125 36 (88) 41 0.23 0.18
Basal LV longitudinal strain — % −16.1±3.9 1125 −15.2±3.5 41 0.14 0.10
Mid-LV longitudinal strain — % −16.7±3.2 1125 −159±3.7 41 0.13 0.07
Apical LV longitudinal strain — % −19.5±5.0 1125 −18.6±4.0 41 0.23 0.17
LV global radial strain — % 24.3±8.2 1125 22.8±7.6 41 0.25 0.22
LV global circumferential strain — % −26.9±4.4 836 −26.5±6.2 34 0.58 0.40
* Plus–minus values are means ±SD. Between-group differences were analyzed with the use of Fisher’s exact test or Pearson’s chi-square test 
for categorical variables and the Mann–Whitney U test or t-test for continuous variables. LV denotes left ventricular.
† The values were adjusted according to age and sex with the use of linear regression or logistic-regression models.
‡ Relative wall thickness was calculated as (2 × the posterior wall thickness measured at end diastole in centimeters) ÷ the end-diastolic diame-
ter of the left ventricle in centimeters.
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out differences in cardiac structure and function 
according to sex.
Some limitations of this analysis should be 
noted. First, the absolute number of V122I carri-
ers was low. Second, genotype status was un-
known for approximately 10% of blacks enrolled 
in the ARIC study, although there were minimal 
differences between those with a known geno-
type status and those with an unknown status, 
making substantial bias unlikely. Third, we can-
not exclude the possibility that the low number 
of male carriers as compared with female carri-
ers at visit 5 was due to more aggressive cardiac 
amyloid involvement in men. However, the absence 
of echocardiographic abnormalities in those who 
died before visit 5 argues against this, and the 
sex distribution according to carrier status at visit 
5 was proportional to that in the recruited co-
hort. Because endomyocardial biopsy specimens 
or autopsy specimens were not available, we can-
not rule out some degree of cardiac involvement 
in carriers. Finally, we cannot rule out an increase 
in mortality among carriers of up to 36%, and our 
data raise the possibility that excess mortality may 
be associated with increasing age. Thus, increased 
mortality might be observed in a larger or older 
cohort.
In summary, we did not detect a greater risk 
of death among V122I TTR allele carriers than 
among noncarriers, although we did observe an 
increased risk of heart failure. The prevalence of 
overt cardiac abnormalities among carriers was 
lower than expected, although carriers had 
subtle impairments of systolic and diastolic 
function. These data suggest that amyloidosis 
associated with the V122I TTR variant may be 
more benign than previously thought, although 
elderly persons who carry this variant may be at 
modestly increased risk for heart failure.
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